title: Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
abstract: Based on encouraging results of a recently published study on the clinical usefulness of oral pentoxifylline (PTX) to reduce transplant-related toxicities, prophylactic pentoxifylline was administered to 31 consecutive allogeneic BMT recipients with hematological malignancies. Patients received PTX as a continuous infusion at increasing dose levels (0.50, 0.75, 1.00 and 1.25 mg/kg/h) starting 1 day prior to the conditioning regimen. At all dose levels, PTX was well tolerated with no significant side-effects. When compared with a historical control group of 61 consecutively transplanted allogeneic BMT recipients, PTX patients did not appear to experience less gastrointestinal (moderate and severe mucositis: 100% vs 68%, p < 0.001), hepatic (hyperbilirubinemia > 1.5 mg/dl: 84% vs 30%, p < 0.001) or renal (creatinine > 1.5 mg/dl: 16% vs 27%, NS) toxicity or to have a lower incidence of GVHD > or = grade III (21% vs 22%, NS). Using i.v. PTX, we were unable to reproduce the reduction in morbidity and mortality in patients undergoing BMT which has been described for prophylactic oral PTX.
authors.affiliation: BMT Unit, University Hospital Eppendorf, Hamburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Stockschläder
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.forename: S
authors.initials: S
authors.lastname: Peters
authors.forename: W
authors.initials: W
authors.lastname: Zeller
authors.forename: W
authors.initials: W
authors.lastname: Krüger
authors.forename: H
authors.initials: H
authors.lastname: Kabisch
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: A
authors.initials: A
authors.lastname: Zander
mesh_terms: D000293:Adolescent; D000328:Adult; D016465:Bone Marrow Purging / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002066:Busulfan; D002648:Child; D003520:Cyclophosphamide; D005047:Etoposide; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D015994:Incidence; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D014916:Whole-Body Irradiation
chemical_list: D014409:Tumor Necrosis Factor-alpha; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan; D010431:Pentoxifylline